J&J stock hits a 52-week high, but key drug patent risks and a lower Wall Street price target suggest downside.
Q4 2025 Earnings Call February 24, 2026 4:30 PM ESTCompany ParticipantsByron Jeffers - VP, Treasurer & Head of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results